- Trial Phase
- Phase 1 completed
- Time to Market
- Unknown; several years away at minimum. The program is stalled at Phase 1 with clinical holds in both the US and UK, and the company is developing backup compounds to address mutagenicity concerns.
- Why 3/10
- No hard dated catalyst exists for tivoxavir marboxil in the next ~12 months. The drug is on FDA clinical hold (mutagenicity concerns) and a planned UK Phase 2a challenge trial was deferred after a negative regulatory review. There is no scheduled PDUFA, pivotal readout, or other binary event — the next catalyst (clinical hold resolution) has no timeline. ImpactScore is 3 per the rubric: a mid-stage drug with no pending binary catalyst.
Avoid TRAW until there is a clear path to resolving the FDA clinical hold AND the UK regulatory impasse. The stock has already fallen ~77% from its 52-week high of $3.27 to ~$0.76. The company has only ~$5M cash (runway into Q1 2027), a going-concern qualification, and a $139M shelf overhang — any positive catalyst is years away, while near-term dilution risk is acute.
Price Chart
Executive Summary
Tivoxavir marboxil is Traws Pharma's lead asset — an oral antiviral for influenza that works via the same cap-dependent endonuclease mechanism as Roche's approved Xofluza. Phase 1 data showed good safety and maintained drug levels above the efficacy threshold for over 23 days from a single dose. However, the program has hit dual regulatory walls: in February 2026 the FDA placed the IND on clinical hold over mutagenicity data concerns, and in June 2026 the UK MHRA issued a negative review that forced deferral of the planned Phase 2a human challenge trial — a trial tied to $20M in funding. The company is now developing backup drug candidates. Traws Pharma is financially distressed (~$10M market cap, ~$5M cash, going concern, $647M accumulated deficit), and both covering analysts (HC Wainwright, Ladenburg Thalmann) downgraded from Buy to Neutral in June 2026. With no hard catalyst date for clinical hold resolution, the drug offers no near-term binary event for investors.
How It Works
An oral antiviral pill (prodrug) that, once ingested, converts to an active form that blocks an essential flu virus enzyme called cap-dependent endonuclease (CEN). This enzyme is how the virus hijacks human cells to replicate itself. By blocking it, the drug stops the virus from multiplying. It is a structural analog of Roche's already-approved flu drug Xofluza (baloxavir marboxil) and is designed as a potential single-dose treatment and once-monthly prophylactic for seasonal flu and pandemic bird flu (H5N1).
Trial Status
Two Phase 1 trials completed (Jan 2025) showing safety, tolerability, and drug levels above EC90 for >23 days. An IND was filed with the FDA in January 2026, but the FDA placed it on clinical hold in February 2026 citing concerns with the mutagenicity data package. A planned Phase 2a human influenza challenge study in the UK was deferred in June 2026 after the MHRA issued a "negative review." The company is developing backup candidates that match the original drug's profile without mutagenic potential.
The Two-Sided Case
Upcoming Catalysts
- Resolution of FDA clinical hold on tivoxavir marboxil IND — no specific date
- Potential BARDA contract for strategic stockpile — contingent on clinical hold resolution
- Possible UK regulatory re-engagement for Phase 2a human challenge trial
- Development and IND filing of backup candidates without mutagenic potential
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Traws Pharma, Inc. 424B5 TRAW ·Originating report